Heart failure & cardiomyopathies
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Authors' conclusion
SGLT2is demonstrate common (fatty acid) and distinct (ketogenic) metabolic signatures across the LVEF spectrum.
Study context
- Population
- Patients with HFrEF (DEFINE-HF) or HFpEF (PRESERVED-HF)
- Participants
- 527 patients2 RCTs
- Comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Changes in principal components analysis-defined metabolite factors (61 metabolites)
- Follow-up
- Baseline to 12 weeks
Methodological detailsplacebo-controlled, metabolomic profiling
- Placebo-controlled
- Metabolomic profiling
Primary result
As reported in the abstract
Metabolite changes · 12 weeks
- Increases in several acylcarnitines consistent across LVEF
- Pinteraction>0.10
- Ketogenic effect diminished at higher LVEF (3-hydroxybutyrate)
- Pinteraction=0.01
Further findings
Ketosis (3-hydroxybutyrate >500 μM)
P = 0.03
Metabolite changes and heart failure (HF)-related outcomes
- Increases in long-chain acylcarnitines and aromatic amino acids and decreases in branched-chain amino acids associated with worse HF-related outcomes, consistent across treatment and LVEF
Original publication
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circ Heart Fail. Published 18 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →